Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in ADHF

Heart Decompensation Clinical Trial

Official title:

Comparison of Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in Patients With Acute Decompensated Heart Failure: A Randomized Controlled Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02649998
• Other study ID #: CRE.2015.592-T
• Status: Withdrawn
• Phase: N/A
• Start date: January 2017
• Est. completion date: June 2022

Study information

• Verified date: March 2023
• Source: Chinese University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background:

Acute decompensated heart failure (ADHF) is a common and potentially fatal cause of acute respiratory distress that requires immediate treatment in emergency department. The mortality rates are as high as 20% after discharge. Currently, furosemide is the most commonly used medicine in emergency department for ADHF. Although nitrate was proved to generate similar effect when compared to furosemide, less than 30% of patients received nitrates. This practice happens not only in Hong Kong, but also all around the world. Moreover, there is limited evidence to support a difference in ADHF patients receiving intravenous nitrate vasodilator therapy or alternative interventions.

The aims of the study are:

1. To monitor the changes in concentration of cardiac biomarkers, VAS dyspnoea score and cardiac output before and after treatment of furosemide, isosorbide dinitrate or both.

2. To investigate whether the changes in concentration of cardiac biomarkers, VAS dyspnoea score and cardiac output before and after treatment is associated with the change in length of hospital stay.

3. To investigate whether combination treatment with intravenous furosemide and isosorbide dinitrate in patients with HF reduces VAS dyspnoea score, in-hospital mortality, length of hospital stay and number of readmission to a higher extend than do either medication alone.

4. To evaluate the prognostic values of novel cardiac biomarkers on 7-day, 14-day, 30-day and 6-month mortality and readmission.

Design:

This single-blinded randomized controlled study will be conducted in the Prince of Wales Hospital in Hong Kong.

Setting and Subjects:

Patients with dyspnoea will be screened and recruited from adult patients attending the emergency department at the Prince of Wales Hospital.

Interventions:

Patients with acute decompensated heart failure will be randomly treated with intravenous furosemide, isosorbide dinitrate or both. Level of dyspnoea, multi-biomarker and haemodynamic parameters will be measured before and after treatment.

Outcomes:

The primary outcome is the change in VAS dyspnoea score after treatment of furosemide, isosorbide dinitrate or both. The secondary outcomes are the changes in concentration of biomarkers and cardiac output, the number of in-hospital mortality, length of hospital stay, 7-day and 30-day and 6-month mortality and readmission.

Description:

Definitions:

Heart failure can be defined as an abnormality of cardiac structure or function leading to failure of the heart to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues, despite normal filling pressures (or only at the expense of increased filling pressures).

Acute decompensated Heart Failure (ADHF), is defined according to Framingham criteria as a change in symptoms and signs in the context of heart failure. For this study we define this as an acute change in symptoms and signs within the previous 24 hours.

In the New York Heart Association classification (NYHA), Class I: no limitation is experienced in any activities; there are no symptoms from ordinary activities.; Class II: slight, mild limitation of activity; the patient is comfortable at rest or with mild exertion.; Class III: marked limitation of any activity; the patient is comfortable only at rest.; Class IV: any physical activity brings on discomfort and symptoms occur at rest.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients aged 18 years or older with increased dyspnoea within the previous 24 hours

• Diagnosed as heart failure by physician

Exclusion Criteria:

• Women with known or suspected pregnancy; myocardial infarction or cardiac surgery within the previous three months;

• Oxygen saturation of less than 85% on room air;

• Respiratory rate greater than 30 breaths/min;

• pH<7.35; systolic blood pressure < 110 bpm;

• Current treatment with oral nitrates in excess of 40 mg daily;

• Current treatment with oral furosemide in excess of 80 mg daily;

• Previous adverse reaction to the study drugs;

• Requirement of noninvasive ventilation;

• Severe renal failure (creatinine >200 µmol/L)

Related Conditions & MeSH terms

• Heart Decompensation
• Heart Failure

Intervention

Drug:
• Furosemide
Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.
• Isosorbide Dinitrate
Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.

Locations

Country	Name	City	State
Hong Kong	Prince of Wales Hospital	Sha Tin	NT

Sponsors (1)

Lead Sponsor	Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The change in VAS dyspnoea score after randomized treatment	Patients will be asked to indicate their status of dyspnoea using a visual analogue scale (VAS). They will be asked to make a mark on a 100 mm uncalibrated horizontal line in sitting (patients head at = 600 relative to horizontal) and supine positions. The mark will be converted to a score (0-100 points) by measuring the distance from the left end. A VAS dyspnoea score of 0 corresponds to the patient's subjective feeling of "I can breathe normally" and a score of 100 represent to "I cannot breathe at all".	24 hour after recruitment
Secondary	The changes in concentration of biomarkers (including BNP, NTproBNP, NGAL, hs-CRP and ST2) after randomized treatment	5mL venous blood will be collected and applied to BNP, NTproBNP, NGAL and hs-CRP rapid test at baseline, 3 hours and 24 hours after randomized treatment at ED. The remaining blood will be centrifuged and stored at -20oC for ST2 measurement.	24 hour after recruitment
Secondary	The changes in volume of blood pumped by the ventricle per minute (cardiac output) after randomized treatment	The cardiac output will be measured using an ultrasonic cardiac output monitor at baseline, 3 hours and 24 hours after randomized treatment at ED.	24 hour after recruitment
Secondary	The number of in-hospital mortality		An average of 5 days
Secondary	Number of day stayed in hospital		An average of 5 days
Secondary	Number of mortality and readmission at 7-day, 14-day, 30-day and 6-month		6-month after recruitment